BioSpace News Archive

TRACK Research Study Designed to Provide Genomically-Informed Treatment Recommendations to Patients while Advancing Genomic Characterization of Rare Cancers

Salarius Pharmaceuticals, Inc., a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced the continued enhancement of the intellectual property portfolio governing its lead investigational drug candidate, seclidemstat.

Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction

Amplyx Pharmaceuticals , a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced its president and chief executive officer, Ciara Kennedy , Ph.D., will present a corporate overview at the following upcoming inve

Pall Corporation, a global leader in filtration, separation and purification, was selected by the United States Department of Defense to receive a $4.9M contract to build a new breathing filter manufacturing line within an existing U.S.-based Pall manufacturing facility to increase ventilator filter production.

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today introduced a new highly automated, real-time PCR solution designed to analyze up to 6,000 samples in a single day to meet increasing global demand for COVID-19 testing. The high-throughput system enables laboratories to double or even triple their te

For the six months ended June 30, 2020, Net Revenues Increase 104% and Operating Expenses Decrease by 17% Peer-Reviewed Research Published, Launch of AAVSB-Accredited Veterinary Continuing Education Program and Wide-Ranging Distribution Agreements with Key Partners Lay the Foundation for Sustained Growth.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the virtual 2020 Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2020 at 8:00am ET. A webcast of the presentation will be available on the investors section of the Company’s website, www.catabasis.com , and will be

Versant Ventures today announced the debut of Matterhorn Biosciences AG, a biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that

Transforming the treatment of aortic disorders, Endologix ® Inc. (OTC: ELGXQ) (“Endologix” or the “Company”), today announced that it has received a CE Mark for the ALTO™ Abdominal Stent Graft System (ALTO). “We are very excited to receive a CE Mark for the ALTO system, that has been achieved through a strong partnership and collaboration with our European notified body, NSAI ” commented Matt Thompson, Chief Medical